Literature DB >> 34690593

Update on Major Neurocognitive Disorders.

Kristin C Jones1.   

Abstract

Dementia is a syndrome characterized by a gradually progressive course that spans a continuum from preclinical symptoms to major impairment in two or more cognitive domains with functional decline. In this review, the author examines some of the more common dementia syndromes from among dozens of different diseases. Findings show that as the U.S. population continues to age, the number of Americans with dementia is expected to rise drastically over the next several decades. This upsurge will contribute to increased health care costs and will have a significant public health impact. Neurodegenerative disorders such as Alzheimer's disease, frontotemporal degeneration, and alpha-synucleinopathies (e.g., Lewy body disease and Parkinson's disease) are some of the more prevalent causes for dementia. In recent years, advancements in neuroimaging, understanding of genetic contributions and pathological changes, and the development of novel biomarkers have fueled clinical understanding of these disorders. However, substantial disease-modifying therapies are still lagging. The advent of future interventions hinges on the ability to discern the distinct clinico-pathologic profiles of the various dementia syndromes and to identify reliable biomarkers for utilization in clinical trials.
Copyright © 2021 by the American Psychiatric Association.

Entities:  

Keywords:  Geriatric psychiatry; Neurocognitive disorders

Year:  2021        PMID: 34690593      PMCID: PMC8475931          DOI: 10.1176/appi.focus.20210004

Source DB:  PubMed          Journal:  Focus (Am Psychiatr Publ)        ISSN: 1541-4094


  82 in total

1.  Dementia in Parkinson's disease: common and treatable.

Authors:  Ian McKeith
Journal:  Lancet Neurol       Date:  2004-08       Impact factor: 44.182

2.  Dementia with Lewy bodies and Parkinson's disease with dementia: are they different?

Authors:  Yoshio Tsuboi; Dennis W Dickson
Journal:  Parkinsonism Relat Disord       Date:  2005-06       Impact factor: 4.891

Review 3.  Epidemiology of alpha-synucleinopathies: from Parkinson disease to dementia with Lewy bodies.

Authors:  R Savica; B F Boeve; G Logroscino
Journal:  Handb Clin Neurol       Date:  2016

4.  Rivastigmine for dementia associated with Parkinson's disease.

Authors:  Murat Emre; Dag Aarsland; Alberto Albanese; E Jane Byrne; Günther Deuschl; Peter P De Deyn; Franck Durif; Jaime Kulisevsky; Teus van Laar; Andrew Lees; Werner Poewe; Alain Robillard; Mario M Rosa; Erik Wolters; Peter Quarg; Sibel Tekin; Roger Lane
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

Review 5.  Dementia.

Authors:  Seth A Gale; Diler Acar; Kirk R Daffner
Journal:  Am J Med       Date:  2018-02-06       Impact factor: 4.965

6.  Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia.

Authors:  J O Rinne; M Laine; V Kaasinen; M K Norvasuo-Heilä; K Någren; H Helenius
Journal:  Neurology       Date:  2002-05-28       Impact factor: 9.910

7.  Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry.

Authors:  E J Burton; G Karas; S M Paling; R Barber; E D Williams; C G Ballard; I G McKeith; P Scheltens; F Barkhof; J T O'Brien
Journal:  Neuroimage       Date:  2002-10       Impact factor: 6.556

Review 8.  Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management.

Authors:  Olivier Piguet; Michael Hornberger; Eneida Mioshi; John R Hodges
Journal:  Lancet Neurol       Date:  2010-12-10       Impact factor: 44.182

9.  Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia.

Authors:  William W Seeley; Richard Crawford; Katya Rascovsky; Joel H Kramer; Michael Weiner; Bruce L Miller; Maria Luisa Gorno-Tempini
Journal:  Arch Neurol       Date:  2008-02

Review 10.  Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.

Authors:  Ian G McKeith; Bradley F Boeve; Dennis W Dickson; Glenda Halliday; John-Paul Taylor; Daniel Weintraub; Dag Aarsland; James Galvin; Johannes Attems; Clive G Ballard; Ashley Bayston; Thomas G Beach; Frédéric Blanc; Nicolaas Bohnen; Laura Bonanni; Jose Bras; Patrik Brundin; David Burn; Alice Chen-Plotkin; John E Duda; Omar El-Agnaf; Howard Feldman; Tanis J Ferman; Dominic Ffytche; Hiroshige Fujishiro; Douglas Galasko; Jennifer G Goldman; Stephen N Gomperts; Neill R Graff-Radford; Lawrence S Honig; Alex Iranzo; Kejal Kantarci; Daniel Kaufer; Walter Kukull; Virginia M Y Lee; James B Leverenz; Simon Lewis; Carol Lippa; Angela Lunde; Mario Masellis; Eliezer Masliah; Pamela McLean; Brit Mollenhauer; Thomas J Montine; Emilio Moreno; Etsuro Mori; Melissa Murray; John T O'Brien; Sotoshi Orimo; Ronald B Postuma; Shankar Ramaswamy; Owen A Ross; David P Salmon; Andrew Singleton; Angela Taylor; Alan Thomas; Pietro Tiraboschi; Jon B Toledo; John Q Trojanowski; Debby Tsuang; Zuzana Walker; Masahito Yamada; Kenji Kosaka
Journal:  Neurology       Date:  2017-06-07       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.